Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism

American Journal of Hematology

Volumn 86, Issue 7, 2011, Pages 603-606

  Hillis, Chris ^a   Warkentin, Theodore E ^a   Taha, Karim ^a   Eikelboom, John W ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PHENYTOIN; WARFARIN;

AGED; ANAPHYLAXIS; ANTICOAGULATION; AORTA VALVE DISEASE; ARTICLE; CASE REPORT; CHILL; DRUG DOSE INCREASE; HEART VALVE BIOPROSTHESIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIMB PAIN; MALE; PRIORITY JOURNAL; SEIZURE; ULTRASOUND; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

AGED; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LOWER EXTREMITY; MALE; PAIN; VENOUS THROMBOEMBOLISM;

EID: 79959332217     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22043     Document Type: Article

References (25)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010; 121: 948-954.
2. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76: 2121-2131.
3. Bonow RO, Carabello BA, Chatterjee K, et al. American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118: e523-661.
4. Lurie Y, Loebstein R, Kurnik D, et al. Warfarin and vitamin K in the era of pharmacogenetics. Br J Clin Pharmacol 2010; 70: 164-170.
5. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edition). Chest 2008; 133(6 Suppl): 160S-198S.
6. Meijer K, Kim YK, Schulman S. Decreasing warfarin sensitivity during the first three months after heart valve surgery: Implications for dosing. Thromb Res 2010; 125: 224-229.
7. Brandjes DP, Heijboer H, Büller H, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485-1489.
8. Falanga A, Zacharski L. Deep vein thrombosis in cancer: The scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701.
9. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-812.
10. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 454S-545S.
11. Mims M, Manian P, Rice L. Acute cardiorespiratory collapse from heparin: A consequence of heparin-induced thrombocytopenia. Eur J Haematol 2004; 72: 366-369.
12. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-Induced Thrombocytopenia, 4th ed. New York: Informa Healthcare USA; 2007. pp 21-66.
13. Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 2009; 8: 129-144.
14. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
15. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502-506.
16. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136: 210-215.
17. Stahl RL, Javid JP, Lackner H. Unrecognized pulmonary embolism presenting as disseminated intravascular coagulation. Am J Med 1984; 76: 772-778.
18. Warkentin TE. Fondaparinux: Does it cause HIT? can it treat HIT? Exp Rev Hematol 2010; 3: 567-581.
19. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(6 Suppl.): 340S-380S.
20. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004; 164: 66-70.
21. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008; 121: 632-636.
22. Davey MG, Lander H. Effect of adenosine diphosphate on circulating platelets in man. Nature 1964; 201: 1037-1039.
23. Khairy M, Lasne D, Amelot A, et al. Polymorphonuclear leukocyte and monocyte activation induced by plasma from patients with heparin-induced thrombocytopenia in whole blood. Thromb Haemost 2004; 92: 1411-1419.
24. Hartman V, Malbrain M, Daelemans R, et al. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: Safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract 2006; 104: c143-c148.
25. Warkentin TE, Davidson BL, Buller HR, et al. Prevalence and risk of pre-existing heparin-induced thrombocytopenia antibodies in patients with acute venous thromboembolism. Chest 2011 Mar 10. [Epub ahead of print].